Integra lifesciences (NASDAQ:IART)‘s stock had its “buy” rating reiterated by equities research analysts at Oppenheimer in a research note issued to investors on Wednesday.
A number of other research analysts have also recently commented on the company. Cantor Fitzgerald restated a “neutral” rating and issued a $52.00 target price on shares of Integra lifesciences in a research note on Friday, January 5th. Zacks Investment Research upgraded Integra lifesciences from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. BidaskClub upgraded Integra lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, March 23rd. Barclays reiterated a “hold” rating and set a $53.00 price objective on shares of Integra lifesciences in a research note on Tuesday, January 9th. Finally, Raymond James reiterated a “market perform” rating and set a $55.00 price objective on shares of Integra lifesciences in a research note on Tuesday, January 2nd. Eleven analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $55.82.
IART opened at $58.98 on Wednesday. The company has a market capitalization of $4,316.81, a PE ratio of 30.40, a PEG ratio of 1.69 and a beta of 0.65. The company has a debt-to-equity ratio of 1.85, a current ratio of 2.36 and a quick ratio of 1.51. Integra lifesciences has a 52 week low of $41.51 and a 52 week high of $59.30.
Integra lifesciences (NASDAQ:IART) last released its earnings results on Wednesday, April 25th. The life sciences company reported $0.58 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.09. The company had revenue of $357.10 million during the quarter, compared to analysts’ expectations of $349.15 million. Integra lifesciences had a return on equity of 16.94% and a net margin of 5.45%. The firm’s revenue for the quarter was up 38.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.39 EPS. research analysts expect that Integra lifesciences will post 2.33 earnings per share for the current fiscal year.
In other Integra lifesciences news, VP Glenn Coleman sold 8,769 shares of Integra lifesciences stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $56.10, for a total value of $491,940.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christian S. Schade sold 15,658 shares of Integra lifesciences stock in a transaction on Monday, March 5th. The stock was sold at an average price of $52.88, for a total value of $827,995.04. Following the completion of the sale, the director now directly owns 75,262 shares of the company’s stock, valued at approximately $3,979,854.56. The disclosure for this sale can be found here. Insiders have sold 79,765 shares of company stock valued at $4,314,208 in the last quarter. 5.10% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Integra lifesciences by 38.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock worth $182,000 after purchasing an additional 1,054 shares in the last quarter. Xact Kapitalforvaltning AB bought a new stake in shares of Integra lifesciences in the 4th quarter worth $311,000. Campbell Newman Asset Management Inc. increased its holdings in shares of Integra lifesciences by 21.5% in the 4th quarter. Campbell Newman Asset Management Inc. now owns 6,964 shares of the life sciences company’s stock worth $333,000 after purchasing an additional 1,234 shares in the last quarter. Stone Ridge Asset Management LLC bought a new stake in shares of Integra lifesciences in the 4th quarter worth $360,000. Finally, Virtu Financial LLC bought a new stake in shares of Integra lifesciences in the 4th quarter worth $378,000. 90.36% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Integra lifesciences’ (IART) “Buy” Rating Reaffirmed at Oppenheimer” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/26/integra-lifesciences-iart-buy-rating-reaffirmed-at-oppenheimer.html.
Integra lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.